Compare US Global Jets ETF (JETS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs TG Therapeutics Inc — how do they compare? US Global Jets ETF trades at $27.45 (market cap $878.48M), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 9.3× US Global Jets ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 26 Days and TG Therapeutics Inc for 16 Days on average.
| JETS | TGTX | |
|---|---|---|
Market Cap | $878.48M | $8.16B |
Volume | 4,465,925 | 1,735,121 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $59.06 |
52-Week Low | $23.64 | $26.94 |
Typical Hold Time | 26 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The U.S. Global Jets ETF (JETS) is trading at $27.475, down 0.7% on the day, with a bearish technical signal from moving averages but a neutral reading from oscillators. Recent news highlights competitive pressure from aerospace and defense ETFs like ARKX and ITA, which have outperformed JETS, while rising jet fuel costs due to Middle East tensions pose headwinds for airline profitability. Key support is at $27, with resistance at $28.
The outlook for JETS is challenged by high fuel expenses and underperformance relative to defense-focused peers, though travel demand remains a potential catalyst. Risks include volatile oil prices and geopolitical uncertainty, while analyst sentiment is cautious given cost pressures and competitive ETF alternatives.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
